368
Views
41
CrossRef citations to date
0
Altmetric
Review

Polycation-based nanoparticle delivery for improved RNA interference therapeutics

&
Pages 1811-1822 | Published online: 22 Nov 2007

Bibliography

  • FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806-811.
  • ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498.
  • MORRIS KV, CHAN SW, JACOBSEN SE, LOONEY DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 305:1289-1292.
  • MORRIS KV: Therapeutic potential of siRNA-mediated transcriptional gene silencing. Biotechniques (2006) (Suppl.):7-13.
  • BODEN D, PUSCH O, SILBERMANN R, LEE F, TUCKER L, RAMRATNAM B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res. (2004) 32:1154-1158.
  • KRUTZFELDT J, RAJEWSKY N, BRAICH R et al.: Silencing of microRNAs in vivo with ‘antagomirs’. Nature (2005) 438:685-689.
  • KRUTZFELDT J, KUWAJIMA S, BRAICH R et al.: Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. (2007) 35:2885-2892.
  • XIE FY, WOODLE MC, LU PY: Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today (2006) 11:67-73.
  • BEHLKE MA: Progress towards in vivo use of siRNAs. Mol. Ther. (2006) 13:644-670.
  • CZAUDERNA F, FECHTNER M, DAMES S et al.: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. (2003) 31:2705-2716.
  • VENTUROLI D, RIPPE B: Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Renal Physiol. (2005) 288:F605-F613.
  • BRAASCH DA, PAROO Z, CONSTANTINESCU A et al.: Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. (2004) 14:1139-1143.
  • LEWIS DL, HAGSTROM JE, LOOMIS AG, WOLFF JA, HERWEIJER H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. (2002) 32:107-108.
  • MCCAFFREY AP, MEUSE L, PHAM TT, CONKLIN DS, HANNON GJ, KAY MA: RNA interference in adult mice. Nature (2002) 418:38-39.
  • SOUTSCHEK J, AKINC A, BRAMLAGE B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432:173-178.
  • BARTON GM, MEDZHITOV R: Retroviral delivery of small interfering RNA into primary cells. Proc. Natl. Acad. Sci. USA (2002) 99:14943-14945.
  • XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. (2002) 20:1006-1010.
  • GRIMM D, PANDEY K, KAY MA: Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol. (2005) 392:381-405.
  • POUTON CW, SEYMOUR LW: Key issues in non-viral gene delivery. Adv. Drug Deliv. Rev. (2001) 46:187-203.
  • READ ML, LOGAN A, SEYMOUR LW: Barriers to gene delivery using synthetic vectors. Adv. Genet. (2005) 53:19-46.
  • ELOUAHABI A, RUYSSCHAERT JM: Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. (2005) 11:336-347.
  • TORCHILIN VP: Drug targeting. Eur. J. Pharm. Sci. (2000) 11(Suppl. 2):S81-S91.
  • TORCHILIN VP: Multifunctional nanocarriers. Adv. Drug Deliv. Rev. (2006) 58:1532-1555.
  • TORCHILIN VP: Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. (2007) 9:E128-E147.
  • MOGHIMI SM, SZEBENI J: Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. (2003) 42:463-478.
  • SIMOES S, FILIPE A, FANECA H et al.: Cationic liposomes for gene delivery. Expert Opin. Drug Deliv. (2005) 2:237-254.
  • OUPICKY D, OGRIS M, SEYMOUR LW: Development of long-circulating polyelectrolyte complexes for systemic delivery of genes. J. Drug Target. (2002) 10:93-98.
  • BOUSSIF O, LEZOUALC'H F, ZANTA MA et al.: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA (1995) 92:7297-7301.
  • LUNGWITZ U, BREUNIG M, BLUNK T, GOPFERICH A: Polyethylenimine-based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. (2005) 60:247-266.
  • SCHIFFELERS RM, ANSARI A, XU J et al.: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. (2004) 32:E149.
  • URBAN-KLEIN B, WERTH S, ABUHARBEID S, CZUBAYKO F, AIGNER A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. (2005) 12:461-466.
  • GRZELINSKI M, URBAN-KLEIN B, MARTENS T et al.: RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. (2006) 17:751-766.
  • OUPICKY D, OGRIS M, HOWARD KA, DASH PR, ULBRICH K, SEYMOUR LW: Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol. Ther. (2002) 5:463-472.
  • HOWARD KA, DASH PR, READ ML et al.: Influence of hydrophilicity of cationic polymers on the biophysical properties of polyelectrolyte complexes formed by self-assembly with DNA. Biochim. Biophys. Acta (2000) 1475:245-255.
  • DASH PR, READ ML, FISHER KD et al.: Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin. J. Biol. Chem. (2000) 275:3793-3802.
  • GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA (2004) 101:8676-8681.
  • THOMAS M, LU JJ, GE Q, ZHANG C, CHEN J, KLIBANOV AM: Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. USA (2005) 102:5679-5684.
  • POSTE G, BUCANA C, RAZ A, BUGELSKI P, KIRSH R, FIDLER IJ: Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. (1982) 42:1412-1422.
  • OGRIS M, WALKER G, BLESSING T, KIRCHEIS R, WOLSCHEK M, WAGNER E: Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Control. Release (2003) 91:173-181.
  • KUNATH K, MERDAN T, HEGENER O, HABERLEIN H, KISSEL T: Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J. Gene Med. (2003) 5:588-599.
  • GUO W, LEE RL: Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS Pharm. Sci. (1999) 1:E19.
  • KIM SH, MOK H, JEONG JH, KIM SW, PARK TG: Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug. Chem. (2006) 17:241-244.
  • GRAYSON AC, DOODY AM, PUTNAM D: Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. (2006) 23:1868-1876.
  • BARTLETT DW, DAVIS ME: Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. (2007) 18:456-468.
  • HU-LIESKOVAN S, HEIDEL JD, BARTLETT DW, DAVIS ME, TRICHE TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. (2005) 65:8984-8992.
  • HEIDEL JD, YU Z, LIU JY et al.: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA (2007) 104:5715-5721.
  • OCHIYA T, NAGAHARA S, SANO A, ITOH H, TERADA M: Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr. Gene Ther. (2001) 1:31-52.
  • MINAKUCHI Y, TAKESHITA F, KOSAKA N et al.: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. (2004) 32:E109.
  • TAKESHITA F, MINAKUCHI Y, NAGAHARA S et al.: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA (2005) 102:12177-12182.
  • SONG E, ZHU P, LEE SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. (2005) 23:709-717.
  • BAIGUDE H, MCCARROLL J, YANG CS, SWAIN PM, RANA TM: Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. (2007) 2:237-241.
  • ZIMMERMANN TS, LEE AC, AKINC A et al.: RNAi-mediated gene silencing in non-human primates. Nature (2006) 441:111-114.
  • PILLE JY, LI H, BLOT E et al.: Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. (2006) 17:1019-1026.
  • MAO HQ, ROY K, TROUNG-LE VL et al.: Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release (2001) 70:399-421.
  • MORRISSEY DV, LOCKRIDGE JA, SHAW L et al.: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. (2005) 23:1002-1007.
  • OGRA P, LAMM ME, MCGHEE JR, MESTECKY J, STROBER W, BIENENSTOCK J: In: Handbook of Mucosal Immunology. Ogra P, Lamm ME, McGhee JR, Mestecky J, Strober W, Bienenstock J (Eds), Academic Press, San Diego, CA, USA (1994).
  • TAMURA S, KURATA T: Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J. Infect. Dis. (2004) 57:236-247.
  • ILLUM L: Nasal drug delivery – possibilities, problems and solutions. J. Control. Release (2003) 87:187-198.
  • BITKO V, MUSIYENKO A, SHULYAYEVA O, BARIK S: Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. (2005) 11:50-55.
  • ZHANG X, SHAN P, JIANG D et al.: Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. (2004) 279:10677-10684.
  • LI BJ, TANG Q, CHENG D et al.: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. (2005) 11:944-951.
  • MASSARO D, MASSARO GD, CLERCH LB: Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 287:L1066-L1070.
  • EYLES JE, BRAMWELL VW, WILLIAMSON ED, ALPAR HO: Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine (2001) 19:4732-4742.
  • HOWARD KA, RAHBEK UL, LIU X et al.: RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. (2006) 14:476-484.
  • LIU X, HOWARD KA, DONG M et al.: The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials (2006) 28:1280-1288.
  • SOANE RJ, FRIER M, PERKINS AC, JONES NS, DAVIS SS, ILLUM L: Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. (1999) 178:55-65.
  • ARTURSSON P, LINDMARK T, DAVIS SS, ILLUM L: Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. (1994) 11:1358-1361.
  • ILLUM L, JABBAL-GILL I, HINCHCLIFFE M, FISHER AN, DAVIS SS: Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. (2001) 51:81-96.
  • KOPING-HOGGARD M, VARUM KM, ISSA M et al.: Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther. (2004) 11:1441-1452.
  • ZHANG W, YANG H, KONG X et al.: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. (2005) 11:56-62.
  • KONG X, ZHANG W, LOCKEY RF, AUAIS A, PIEDIMONTE G, MOHAPATRA SS: Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet. Vaccines Ther. (2007) 5:4.
  • HUANG M, FONG CW, KHOR E, LIM LY: Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J. Control. Release (2005) 106:391-406.
  • ISHII T, OKAHATA Y, SATO T: Mechanism of cell transfection with plasmid/chitosan complexes. Biochim. Biophys. Acta (2001) 1514:51-64.
  • KOPING-HOGGARD M, ISSA MM, KOHLER T, TRONDE A, VARUM KM, ARTURSSON P: A miniaturized nebulization catheter for improved gene delivery to the mouse lung. J. Gene Med. (2005) 7:1215-1222.
  • ZHANG Y, CRISTOFARO P, SILBERMANN R et al.: Engineering mucosal RNA interference in vivo. Mol. Ther. (2006) 14:336-342.
  • PALLISER D, CHOWDHURY D, WANG QY et al.: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2006) 439:89-94.
  • ROY K, MAO HQ, HUANG SK, LEONG KW: Oral gene delivery with chitosan – DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. (1999) 5:387-391.
  • DAMS ET, LAVERMAN P, OYEN WJ et al.: Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. (2000) 292:1071-1079.
  • ROMBERG B, HENNINK WE, STORM G: Sheddable coatings for long-circulating nanoparticles. Pharm. Res. (2007) (In Press).
  • SAWANT RM, HURLEY JP, SALMASO S et al.: “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. (2006) 17:943-949.
  • CARLISLE RC, ETRYCH T, BRIGGS SS, PREECE JA, ULBRICH K, SEYMOUR LW: Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J. Gene Med. (2004) 6:337-344.
  • MEDAROVA Z, PHAM W, FARRAR C, PETKOVA V, MOORE A: In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. (2007) 13:372-377.
  • ANDERSEN MO, HOWARD KA, PALUDAN S, BESENBACHER F, KJEMS J: Delivery of siRNA from lyophilised polymeric surfaces. Biomaterials (2007) (In Press).
  • SCHMITZ T, BRAVO-OSUNA I, VAUTHIER C, PONCHEL G, LORETZ B, BERNKOP-SCHNURCH A: Development and in vitro evaluation of a thiomer-based nanoparticulate gene delivery system. Biomaterials (2007) 28:524-531.
  • OISHI M, NAGASAKI Y, ITAKA K, NISHIYAMA N, KATAOKA K: Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. (2005) 127:1624-1625.
  • READ ML, SINGH S, AHMED Z et al.: A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. (2005) 33:E86.
  • SOUNDARA MANICKAM D, OUPICKY D: Polyplex gene delivery modulated by redox potential gradients. J. Drug Target. (2006) 14:519-526.
  • HENRY SM, EL-SAYED ME, PIRIE CM, HOFFMAN AS, STAYTON PS: pH-responsive poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery. Biomacromolecules (2006) 7:2407-2414.
  • SIMEONI F, MORRIS MC, HEITZ F, DIVITA G: Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. (2003) 31:2717-2724.
  • CROMBEZ L, CHARNET A, MORRIS MC, ALDRIAN-HERRADA G, HEITZ F, DIVITA G: A non-covalent peptide-based strategy for siRNA delivery. Biochem. Soc. Trans. (2007) 35:44-46.
  • RAHBEK UL, HOWARD KA, OUPICKY D et al.: Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J. Gene Med. (2007) (In Press).
  • AKHTAR S, BENTER I: Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. (2007) 59:164-182.
  • LV H, ZHANG S, WANG B, CUI S, YAN J: Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release (2006) 114:100-109.
  • JUDGE AD, BOLA G, LEE AC, MACLACHLAN I: Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. (2006) 13:494-505.
  • YUAN X, LI L, RATHINAVELU A et al.: SiRNA drug delivery by biodegradable polymeric nanoparticles. J. Nanosci. Nanotechnol. (2006) 6:2821-2828.
  • KHAN A, BENBOUBETRA M, SAYYED PZ et al.: Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J. Drug Target. (2004) 12:393-404.
  • LANDEN CN Jr, CHAVEZ-REYES A, BUCANA C et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. (2005) 65:6910-6918.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.